CSCR
MCID: CNT060
MIFTS: 38

Central Serous Chorioretinopathy (CSCR)

Categories: Bone diseases, Eye diseases, Immune diseases, Rare diseases

Aliases & Classifications for Central Serous Chorioretinopathy

MalaCards integrated aliases for Central Serous Chorioretinopathy:

Name: Central Serous Chorioretinopathy 20 58 71
Central Serous Chorioretinopathy After Bone Marrow Transplantation 20
Central Serous Choroidopathy 20
Cscr 58

Characteristics:

Orphanet epidemiological data:

58
central serous chorioretinopathy
Inheritance: Not applicable;

Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

ICD10 via Orphanet 33 H35.7
UMLS via Orphanet 72 C0730328
Orphanet 58 ORPHA443079
UMLS 71 C0730328

Summaries for Central Serous Chorioretinopathy

GARD : 20 Central serous chorioretinopathy is a disease that causes fluid to build up under the retina, the back part of the inner eye that sends sight information to the brain. The fluid leaks from the choroid (the blood vessel layer under the retina). The cause of this condition is unknown but stress can be a risk factor. Signs and symptoms include dim and blurred blind spot in the center of vision, distortion of straight lines and seeing objects as smaller or farther away. Many cases of central serous chorioretinopathy improve without treatment after 1-2 months. Laser treatment may be an option for other individuals.

MalaCards based summary : Central Serous Chorioretinopathy, also known as central serous chorioretinopathy after bone marrow transplantation, is related to choroiditis and kuhnt-junius degeneration. An important gene associated with Central Serous Chorioretinopathy is CFH (Complement Factor H), and among its related pathways/superpathways are Complement and coagulation cascades and Cell adhesion_ECM remodeling. The drugs Eplerenone and Pharmaceutical Solutions have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and bone marrow.

Related Diseases for Central Serous Chorioretinopathy

Diseases related to Central Serous Chorioretinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 248)
# Related Disease Score Top Affiliating Genes
1 choroiditis 31.2 CFH ARMS2
2 kuhnt-junius degeneration 30.8 CFH ARMS2
3 multifocal choroiditis 30.7 CFH ARMS2
4 macular degeneration, age-related, 1 30.6 CFH C4B ARMS2
5 angioid streaks 30.3 CFH ARMS2
6 antiphospholipid syndrome 30.2 SERPINE1 PLAT CFH
7 apnea, obstructive sleep 30.2 SERPINE1 NR3C2
8 bestrophinopathy, autosomal recessive 11.3
9 retinal detachment 11.2
10 microvascular complications of diabetes 5 10.8
11 scotoma 10.7
12 macular retinal edema 10.7
13 sleep apnea 10.7
14 periodontal ehlers-danlos syndrome 10.6
15 uveitis 10.6
16 retinal disease 10.6
17 refractive error 10.6
18 helicobacter pylori infection 10.5
19 vogt-koyanagi-harada disease 10.5
20 retinal vascular disease 10.5
21 eye disease 10.5
22 retinal degeneration 10.5
23 neuritis 10.4
24 neuroretinitis 10.4
25 myopia 10.4
26 retinitis 10.4
27 47,xyy 10.4
28 yemenite deaf-blind hypopigmentation syndrome 10.4
29 coronary heart disease 1 10.4
30 impotence 10.4
31 multiple sclerosis 10.3
32 heart disease 10.3
33 optic neuritis 10.3
34 optic nerve disease 10.3
35 hemangioma 10.3
36 sleep disorder 10.3
37 peptic ulcer disease 10.3
38 ulcerative colitis 10.3
39 gastroesophageal reflux 10.3
40 systemic lupus erythematosus 10.3
41 b-lymphoblastic leukemia/lymphoma 10.3
42 keratoconus 10.3
43 posterior uveitis 10.3
44 telangiectasis 10.3
45 color blindness 10.3
46 acute retrobulbar neuritis 10.3
47 retinal vein occlusion 10.3
48 adenoma 10.3
49 neuropathy 10.3
50 lupus erythematosus 10.3

Graphical network of the top 20 diseases related to Central Serous Chorioretinopathy:



Diseases related to Central Serous Chorioretinopathy

Symptoms & Phenotypes for Central Serous Chorioretinopathy

Drugs & Therapeutics for Central Serous Chorioretinopathy

Drugs for Central Serous Chorioretinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Eplerenone Approved Phase 4 107724-20-9 150310 443872
2 Pharmaceutical Solutions Phase 4
3 diuretics Phase 4
4 Antihypertensive Agents Phase 4
5 Mineralocorticoid Receptor Antagonists Phase 4
6 Diuretics, Potassium Sparing Phase 4
7 Mineralocorticoids Phase 4
8
Brinzolamide Approved Phase 2 138890-62-7 68844
9
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
10
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
11
Ranibizumab Approved Phase 1, Phase 2 347396-82-1 459903
12
Ketoconazole Approved, Investigational Phase 2 65277-42-1 47576
13
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
14
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
15
Copper Approved, Investigational Phase 2 7440-50-8 27099
16
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
17
Tocopherol Approved, Investigational Phase 2 1406-66-2
18
Zinc Approved, Investigational Phase 2 7440-66-6 32051
19
Mifepristone Approved, Investigational Phase 2 84371-65-3 55245
20
Amoxicillin Approved, Vet_approved Phase 1, Phase 2 26787-78-0 33613
21
Omeprazole Approved, Investigational, Vet_approved Phase 1, Phase 2 73590-58-6 4594
22
Metronidazole Approved Phase 1, Phase 2 443-48-1 4173
23
Hydrocortisone acetate Approved, Vet_approved Phase 1, Phase 2 50-03-3
24
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 5754
25
Sodium citrate Approved, Investigational Phase 2 68-04-2
26
Finasteride Approved Phase 2 98319-26-7 57363
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
28
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
29
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067
30
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354
31
Lutein Approved, Investigational, Nutraceutical Phase 2 127-40-2 5281243
32
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 2 83-88-5 493570
33
Manganese Approved, Nutraceutical Phase 2 7439-96-5 27854
34
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
35 Tocotrienol Investigational Phase 2 6829-55-6
36 Anecortave Investigational Phase 1, Phase 2 10184-70-0
37 Carbonic Anhydrase Inhibitors Phase 2
38 Immunosuppressive Agents Phase 2
39 Vitamin B Complex Phase 2
40 Folic Acid Antagonists Phase 2
41 Immunologic Factors Phase 2
42 Antimetabolites Phase 2
43 Vitamin B9 Phase 2
44 Folate Phase 2
45 Antifungal Agents Phase 2
46 Cytochrome P-450 CYP3A Inhibitors Phase 2
47 Cytochrome P-450 Enzyme Inhibitors Phase 2
48 Anti-Infective Agents Phase 2
49 Protective Agents Phase 2
50 retinol Phase 2

Interventional clinical trials:

(show top 50) (show all 66)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomized Controlled Multicentre Trial Comparing Half-dose Photodynamic Therapy (PDT) With High-density Subthreshold Micropulse Laser Treatment in Patients With Chronic Central Serous Chorioretinopathy (CSC) Completed NCT01797861 Phase 4
2 A Randomized, Double-masked, Multicenter, Controlled Study of Photodynamic Therapy in Patients With Central Serous Chorioretinopathy Completed NCT01574430 Phase 4
3 Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population Completed NCT02462499 Phase 4 Inspra (eplerenone)
4 PRedictive Factors and Changes From Treatment in Idiopathic Polypoidal Choroidal Vasuclopathy Versus Central Serous Chorioretinopathy Versus Neovascular Age Related Macular Degeneration With afLibercept Recruiting NCT02681783 Phase 4 aflibercept
5 Study on Half-dose Photodynamic Therapy Versus Eplerenone in Chronic CenTRAl Serous Chorioretinopathy (SPECTRA Trial) Active, not recruiting NCT03079141 Phase 4 Eplerenone
6 Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy Unknown status NCT00418431 Phase 2, Phase 3 Intravitreal injection of Bevacizumab
7 A Randomized, Double-masked, Placebo Controlled Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
8 A Prospective Non-inferiority Study of the Use of Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy Completed NCT02735213 Phase 2, Phase 3
9 Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy Unknown status NCT03542006 Phase 2 Brinzolamide Ophthalmic
10 Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy Unknown status NCT02153125 Phase 2 Eplerenone
11 Phase 2 Study of Escalating Oral Methotrexate for Central Serous Chorioretinopathy Unknown status NCT01633983 Phase 2 Methotrexate;Delayed treatment
12 Phase 2 Study of Non-damaging Retinal Laser Therapy Using PASCAL Laser With Endpoint Management Software for Macular Diseases Unknown status NCT01975103 Phase 2
13 Prospective Study on the Efficacy and Safety of Intravitreal Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01325181 Phase 1, Phase 2 Verteporfin;ranibizumab
14 Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC) Completed NCT00211445 Phase 2 verteporfin
15 Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Completed NCT01971190 Phase 2 Intravitreal Aflibercept injection;Sham injection
16 A Pilot Study of The Treatment of Central Serous Chorioretinopathy With Ketoconazole. Completed NCT00211393 Phase 2 ketoconazole
17 Eplerenone for Central Serous Chorioretinopathy: A Pilot Study Completed NCT01822561 Phase 2 Eplerenone 50mg
18 Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Chorioretinopathy: A Prospective Randomized Controlled Trial Completed NCT00987077 Phase 2
19 High-dose Antioxidants for Central Serous Chorioretinopathy Completed NCT00963131 Phase 2 antioxidants tablets
20 Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC) Completed NCT02354170 Phase 2 Mifepristone;Placebo
21 Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study Completed NCT01710332 Phase 2 Intravitreal Aflibercept Injection
22 Effect of Helicobacter Pylori Treatment on Remission of Idiopathic Central Serous Chorioretinopathy (ICSCR) Completed NCT00817245 Phase 1, Phase 2 omeprazole, Amoxicillin, metronidazole
23 Treatment of Chronic Central Serous Chorioretinopathy With Open-label Anecortave Acetate Completed NCT00489840 Phase 1, Phase 2 Anecortave Acetate Sterile suspension 15 mg;Anecortave Acetate
24 Pilot Phase I/II Study of the Treatment of Classic Central Serous Chorioretinopathy With Topical Interferon Gamma-1b Completed NCT01468337 Phase 1, Phase 2 Interferon gamma-1b
25 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01227993 Phase 1, Phase 2 Finasteride
26 Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT00837252 Phase 1, Phase 2 Finasteride
27 Sildenafil for Treatment of Choroidal Ischemia Recruiting NCT04356716 Phase 2 Sildenafil
28 Phase II, Randomized, Placebo-Controlled Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Terminated NCT01585441 Phase 2 Finasteride;Placebo
29 Phase I Study of Intravitreally Administered Ranibizumab in Subjects With Unresolving CSC and Subfoveal Fluid. Completed NCT00403325 Phase 1 rhuFab V2 [ranibizumab] ( Lucentis )
30 Eye Patching as a Potential Treatment Modality for and a Possible Etiological Insight on Central Serous Retinopathy Completed NCT02036632 Phase 1
31 Phase I Study of Sequestered Transscleral, Controlled-Release Celecoxib Delivered Via Episcleral Reservoir for Treatment of Macular Edema & Inflammatory Disorders of the Eye Posterior Pole Including Sclera, Choroid, Retina or Vitreous Recruiting NCT04120636 Phase 1 Episcleral Celecoxib
32 Phase I Study of Sequestered Transscleral, Controlled-Release Dexamethasone Delivered Via Episcleral Reservoir for Treatment of Macular Edema & Inflammatory Disorders of the Eye Posterior Pole Including Sclera, Choroid, Retina or Vitreous Recruiting NCT04120311 Phase 1 Episcleral Dexamethasone
33 Analysis of Plasminogen Activator Inhibitor-1 Level in Chronic Serous Chorioretinopathy and Polypoidal Choroidal Vasculopathy Unknown status NCT02815176
34 Pseudo-PDT in Central Serous Chorioretinopathy Unknown status NCT02799992
35 Prospective Randomized Controlled Clinical Trial to Evaluate the Effects of 577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy Unknown status NCT02587767
36 The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Unknown status NCT01630863
37 Intraocular Concentrations of Growth Factors and Cytokines in Chronic Central Serous Chorioretinopathy And the Effect of Therapy With Bevacizumab Unknown status NCT00864773
38 The Changes of Retinal and Choroidal Capillaries After Half-dose Photodynamic Therapy Measured by Angio- OCT in Eyes With Central Serous Chorioretinopathy Unknown status NCT03692169
39 Selective RPE Laser Treatment (SRT) for Various Macular Diseases Unknown status NCT00403884
40 Eplerenone for the Treatment of Central Serous Chorioretinopathy Completed NCT01990677 25mg Eplerenone;Placebo
41 Effects of Optical Coherence Tomography Angiography-guided Photodynamic Therapy in Acute Central Serous Chorioretinopathy Completed NCT03497000
42 Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy Completed NCT01019668 Verteporfin PDT, half-dose;verteporfin PDT, half-fluence
43 Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Completed NCT01434095
44 Randomized Controlled Clinical Trial to Evaluate the Effects of 577nm Micropulse Laser vs Traditional Laser Therapy on Acute Central Serous Chorioretinopathy Completed NCT02784665
45 Central Serous Chorioretinopathy: An Observational Study About Etiology, Course and Prognosis Completed NCT01378130
46 Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy: Evaluation by Fundus Autofluorescence and Spectral Domain Optical Coherence Tomography Completed NCT01327170
47 Comparison of Multifocal Electroretinogram Assessment Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy Completed NCT00803517
48 Treatment of Chronic Recalcitrant or Unresponsive Central Serous Chorioretinopathy Via Electromagnetic Stimulation And Platelet- Rich Plasma Completed NCT04224831
49 A Prospective, Multi-center, Randomized, Double-blinded (Subject & Independent Efficacy Evaluator), Comparative Clinical Study to Evaluate the Efficacy and Safety of SRT (Selective Retina Therapy) With 'R:GEN' in Patients With Central Serous Chorioretinopathy Completed NCT03758963
50 Optical Coherence Tomography Angiography (OCT-A) Quantitative Assessment of Choriocapillaris Blood Flow in Central Serous Chorioretinopathy (CSC) Completed NCT03950089

Search NIH Clinical Center for Central Serous Chorioretinopathy

Genetic Tests for Central Serous Chorioretinopathy

Anatomical Context for Central Serous Chorioretinopathy

MalaCards organs/tissues related to Central Serous Chorioretinopathy:

40
Eye, Retina, Bone Marrow, Bone, Endothelial, Neutrophil, Pituitary

Publications for Central Serous Chorioretinopathy

Articles related to Central Serous Chorioretinopathy:

(show top 50) (show all 2124)
# Title Authors PMID Year
1
Choriocapillaris Integrity in Relapsed Central Serous Chorioretinopathy in a Patient Treated With Fingolimod for Multiple Sclerosis: New Insights From Optical Coherence Tomography Angiography. 61
32235227 2021
2
Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil). 61
33364520 2021
3
PHOTORECEPTOR OUTER SEGMENT IS EXPANDED IN THE FELLOW EYE OF PATIENTS WITH UNILATERAL CENTRAL SEROUS CHORIORETINOPATHY. 61
32404847 2021
4
The implications of subretinal fluid in pachychoroid neovasculopathy. 61
33603014 2021
5
Comments on: Monocyte to high-density lipoprotein ratio in central serous chorioretinopathy: A biomarker of inflammation or epiphenomenon. 61
33463624 2021
6
Response to comments on: Monocyte to high-density lipoprotein and neutrophil-to-lymphocyte ratios in patients with acute central serous chorioretinopathy. 61
33463625 2021
7
Characteristics and treatment responses of cystoid retina associated with central serous chorioretinopathy. 61
33532933 2021
8
Comment on: The Effect of Obstructive Sleep Apnea on Absolute Risk of Central Serous Chorioretinopathy. 61
33571471 2021
9
Reply to Comment on: The Effect of Obstructive Sleep Apnea on Absolute Risk of Central Serous Chorioretinopathy. 61
33567302 2021
10
Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy. 61
33307626 2021
11
Structural OCT Parameters Associated with Treatment Response and Macular Neovascularization Onset in Central Serous Chorioretinopathy. 61
33606200 2021
12
Plasma cerebellin levels in patients with central serous chorioretinopathy. 61
33358442 2021
13
Early alterations in retinal microvasculature on swept-source optical coherence tomography angiography in acute central serous chorioretinopathy. 61
33542349 2021
14
Central serous chorioretinopathy in active endogenous Cushing's syndrome. 61
33531597 2021
15
Comparison of the outcomes of photodynamic therapy for central serous chorioretinopathy with or without subfoveal fibrin. 61
32291401 2021
16
Choroidal neovascularization secondary to half-dose photodynamic therapy for chronic central serous chorioretinopathy: A case report. 61
33607835 2021
17
Quantitative Evaluation of Retinal Vessel Density in Central Serous Chorioretinopathy after Half-dose Photodynamic Therapy. 61
33141608 2021
18
Plasma metabolomic profiling of central serous chorioretinopathy. 61
33326810 2021
19
Central Serous Chorioretinopathy and Blood Serotonin Concentrations. 61
33546112 2021
20
Optical coherence tomography angiography of flat irregular pigment epithelial detachments in central serous chorioretinopathy. 61
32265200 2021
21
Optical coherence tomography angiography for the diagnosis of granulomatosis with polyangiitis with serous retinal detachment: A case report. 61
33607834 2021
22
Retinal cross-section motion correction in three-dimensional retinal optical coherence tomography. 61
33576160 2021
23
Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser. 61
33565230 2021
24
THE INCIDENCE OF NEOVASCULARIZATION IN CENTRAL SEROUS CHORIORETINOPATHY BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. 61
32310626 2021
25
Evaluation of the choroidal features in pachychoroid spectrum diseases by optical coherence tomography and optical coherence tomography angiography. 61
31684767 2021
26
[Nanosecond Laser Treatment in Chorioretinopathia Centralis Serosa without RPE Defects: A Retrospective Case Series]. 61
31600817 2021
27
Short-term effect of anti-VEGF for chronic central serous chorioretinopathy according to the presence of choroidal neovascularization using optical coherence tomography angiography. 61
33428683 2021
28
Investigating the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy. 61
33279285 2021
29
Sensitivity and Specificity of Multispectral Imaging For Polypoidal Choroidal Vasculopathy. 61
33512897 2021
30
Drusen and pachydrusen: the definition, pathogenesis, and clinical significance. 61
33208847 2021
31
Macular neovascularization in AMD, CSC and best vitelliform macular dystrophy: quantitative OCTA detects distinct clinical entities. 61
33495568 2021
32
Efficacy and safety of the mineralocorticoid receptor antagonist treatment for central serous chorioretinopathy: a systematic review and meta-analysis. 61
33414535 2021
33
Non-central serous chorioretinopathy in a patient with systemic lupus erythematosus and hydroxychloroquine retinopathy. 61
33462009 2021
34
Bilateral peripapillary serous retinal detachment: Optic pit or atypical presentation of central serous chorioretinopathy? 61
33487445 2021
35
CHOROIDAL THICKNESS CHANGES IN A PATIENT DIAGNOSED WITH CENTRAL SEROUS CHORIORETINOPATHY DURING FOLLOW-UP FOR PACHYCHOROID PIGMENT EPITHELIOPATHY. 61
29470299 2021
36
Central Serous Chorioretinopathy Analyzed by Multimodal Imaging. 61
33510954 2021
37
Morphological Changes and Prognostic Factors before and after Photodynamic Therapy for Central Serous Chorioretinopathy. 61
33440827 2021
38
Fundus Autofluorescence after Half-Dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. 61
33564669 2021
39
REVISED CLASSIFICATION OF THE OPTICAL COHERENCE TOMOGRAPHY OUTER RETINAL BANDS BASED ON CENTRAL SEROUS CHORIORETINOPATHY ANALYSIS. 61
32271277 2021
40
One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy. 61
33430812 2021
41
Dynamic changes and correlation analysis of outer retinal microstructure in macular area of central serous chorioretinopathy patients during restoration period. 61
33420567 2021
42
Light exposure in acute central serous chorioretinopathy. 61
33423042 2021
43
The Role of Imaging in Planning Treatment for Central Serous Chorioretinopathy. 61
33572948 2021
44
Sensitivity and specificity of choroidal thickness measurement by EDI-OCT for central serous chorioretinopathy diagnosis. 61
32886312 2021
45
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY-GUIDED PHOTODYNAMIC THERAPY FOR ACUTE CENTRAL SEROUS CHORIORETINOPATHY. 61
32343102 2021
46
CLINICAL FEATURES OF FLAT IRREGULAR PIGMENT EPITHELIAL DETACHMENT ASSOCIATED WITH CHOROIDAL NEOVASCULARIZATION IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. 61
32251241 2021
47
Systemic Corticosteroid Use after Central Serous Chorioretinopathy Diagnosis. 61
32619546 2021
48
Long-term outcomes of half-fluence photodynamic therapy and eplerenone in chronic central serous chorioretinopathy: A comparative study. 61
33508971 2021
49
Oxidative stress parameters and antioxidant enzyme levels in patients with central serous chorioretinopathy. 61
33473027 2021
50
Central serous chorioretinopathy secondary to solar retinopathy: an unusual presentation. 61
33509892 2021

Variations for Central Serous Chorioretinopathy

Expression for Central Serous Chorioretinopathy

Search GEO for disease gene expression data for Central Serous Chorioretinopathy.

Pathways for Central Serous Chorioretinopathy

Pathways related to Central Serous Chorioretinopathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.09 SERPINE1 PLAT CFH C4B
2 10.94 SERPINE1 PLAT
3 10.07 SERPINE1 PLAT

GO Terms for Central Serous Chorioretinopathy

Biological processes related to Central Serous Chorioretinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibrinolysis GO:0042730 8.62 PLAT SERPINE1

Sources for Central Serous Chorioretinopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....